Drug Profile

Research programme: tolerizing antigen carriers - SQZ Biotech

Alternative Names: Next-Gen-SQZ-TACs; SQZ^® TACs

Latest Information Update: 28 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SQZ Biotech
Class Cell therapies; Gene therapies
Mechanism of Action Cell replacements; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Coeliac disease; Type 1 diabetes mellitus
No development reported Autoimmune disorders

Most Recent Events

28 Jun 2024 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
22 Jun 2022 Pharmacodynamics data from preclinical trials in coeliac disease released by SQZ Biotech

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com